livers ameliorated liver fibrosis in pre-clinical models. Dr. Balakrishnan mentions, “The promising therapeutic potential of microRNAs in the inhibition of fibrosis is due to the fact that a single miRNA can

and in vivo infection studies with human hepatotropic viruses and preclinical evaluation of new therapeutic concepts within the Thematical Translation Unit Hepatitis as well as to support other Thematical

Non-coding RNAs: key regulators of reprogramming, pluripotency, and cardiac cell specification with therapeutic perspective for heart regeneration. Cardiovasc Res. 118(15):3071-3084. https://doi.org/10.1093

Kleinert H (2022) Cell Commun Signal. 20(1):47. https//doi.org/10.1186/s12964-022-00855-x Paving Therapeutic Avenues for FOXG1 Syndrome: Untangling Genotypes and Phenotypes from a Molecular Perspective. Akol

cardioprotective strategies. Our research addresses these dual challenges by focusing on novel therapeutic targets, including various RNAs and RNA-binding proteins, as well as pioneering heart-targeting

: Prof. Dr. Hansmann, Pediatric Cardiology, OE 6730, project: Stem cell and anti-miR-mediated therapeutic interventions for pulmonary vascular disease and right ventricular failure Final exam June 2017

and numerous other membrane remodeling processes. Moreover, dynamin is a promising target for therapeutic intervention in chronic kidney diseases (CKDs). We want to provide the basis for novel strategies

Matthias Jentschke Zeitschrift: Forum- Das offizielle Magazin der Deutschen Krebsgesellschaft e.V. A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical In

Helmholtz Center Munich 13.12.2023 REBIRTH Kolloquium (1 pm s.t., online Vortrag) ‘RNA-based therapeutic strategies for liver injuries’ Prof. Dr. Amar Deep Sharma, Department of Gastroenterology, Hepatology [...] Clinic of Pneumology and Infectiology, MHH ´Genetic skewing of macrophage function to enhance the therapeutic properties’ Schifaa Abdin (Group of Prof. Dr. Nico Lachmann), Department of Applied Stem Cell and [...] for Kidney and Hypertension Diseases, MHH ´Relevance of cardiovascular risk factors for novel therapeutic approaches´ Prof. Dr. Rabea Hinkel, German Primate Centre, Leibniz Institute for Primate Research

Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett 586 , 310-313. PubMed-Link Strotmeier J, Gu S, Jutzi S, Mahrhold